Details for Patent: 8,785,632
✉ Email this page to a colleague
Which drugs does patent 8,785,632 protect, and when does it expire?
Patent 8,785,632 protects XALKORI and is included in two NDAs.
This patent has fifty-three patent family members in forty-five countries.
Summary for Patent: 8,785,632
| Title: | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| Abstract: | Enantiomerically pure compound of formula 1 ##STR00001## are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers. |
| Inventor(s): | Cui; Jingrong Jean (San Diego, CA), Funk; Lee Andrew (Oceanside, CA), Jia; Lei (San Diego, CA), Kung; Pei-Pei (San Diego, CA), Meng; Jerry Jialun (San Diego, CA), Nambu; Mitchell David (San Diego, CA), Pairish; Mason Alan (San Diego, CA), Shen; Hong (San Diego, CA), Tran-Dube; Michelle (La Jolla, CA) |
| Assignee: | Agouron Pharmaceuticals, Inc. (San Diego, CA) Pfizer Inc. (New York, NY) |
| Application Number: | 13/537,759 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 8,785,632
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-001 | Sep 7, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-002 | Sep 7, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-003 | Sep 7, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-001 | Aug 26, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,785,632
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1786785 | ⤷ Sign Up | PA2013005 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1786785 | ⤷ Sign Up | CA 2013 00009 | Denmark | ⤷ Sign Up |
| European Patent Office | 1786785 | ⤷ Sign Up | 92155 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1786785 | ⤷ Sign Up | C300587 | Netherlands | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
